FINWIRES · TerminalLIVE
FINWIRES

$IMMX

4 stories mentioning IMMX

Every FINWIRES story that references IMMX, newest first.

Sectors

Sector Update: Healthcare Stocks Decline Premarket Thursday

Healthcare stocks were declining premarket Thursday, with the iShares Biotechnology ETF (IBB) 1% lower and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.Immix Biopharma (IMMX) shares were up more than 6% after the company said it achieved a 95% complete response rate in a phase 1b/2 trial evaluating NXC-201 for the treatment for relapsed/refractory AL Amyloidosis.Nanobiotix (NBTX) launched a global follow-on offering of 75 million euros ($87.2 million), the clinical-stage biotechnology company said. Nanobiotix stock was down more than 5% pre-bell.Relay Therapeutics (RLAY) shares were up more than 10% after the company said it priced a public offering of 22.9 million common shares at $12 each.

$IBB$IMMX$NBTX$RLAY$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were steady premarket Thursday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down a slight 0.1%.Immix Biopharma (IMMX) shares were nearly 8% higher after the company said it achieved a 95% complete response rate in a phase 1b/2 trial evaluating NXC-201 for the treatment for relapsed/refractory AL Amyloidosis.

$IMMX
Research

Update: Mizuho Keeps Price Target on Immix Biopharma to $15, Maintains Outperform Rating

(Updated to keep price target unchanged).(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $8.57, Change: $-0.04, Percent Change: -0.41%

$IMMX
Wire

Mizuho Adjusts Price Target on Immix Biopharma to $15 From $10, Maintains Outperform Rating

Mizuho Adjusts Price Target on Immix Biopharma to $15 From $10, Maintains Outperform Rating

$IMMX